بسم الله الرحمن الرحيم

قال تعالي :

صدق الله العظيم

Acknowledgment

Praise and thanks are due to ALLAH the lord and creator.

I would to acknowledge. berate, condescend to, or mention people, places, of things that were helpful, instrumental, or played a major or minor part in the doing of the research. First and foremost.

I would like to acknowledge my supervisor Dr/ Mohamed Ahmed: live and in living color from the Radiotherapy and Nuclear Medicine Department, the effervescent, holistic. Many thanks to the fine folks at nuclear medicine department at king fahad medical city Riyadh sudi aribi for helping this really fine research. My thanks go to my ebullient, enthusiastic, and ecologically friendly supervisor for making this research possible and for reminding me when a deadline was about to go whooshing past and for providing copious comments and moral support while keeping us on track. As always, thanks to my friends and family. Radiotherapy and Nuclear Medicine Department Staff: with so many thanks-you have to go around, my first is to them who guided me through my first.

Dedication

My parents, who have been raising me to be the person I am today. They have been with me every step of the way, through good bad. They have been a source if encouragement and inspiration to me throughout my life, a very special thank you for providing a "writing space" and for nurturing me through the months of writing.

Thanks for the un conditional love, guidance, and support they have always given me, helping me to succeed and installing in the confidence that I am capable of doing anything I put mind to. To my brothers and sisters, to my friends, I spent with them most beautiful years.

Abstract

Background:

The lack of anatomical details in standard 131 iodine whole body scanning (1311 WBS) interferes with the proper localization of metastatic differentiated thyroid carcinoma (DTC) lesions. In addition, nearby or overlapping variable physiological distribution of 1311 may affect the specificity of 1311 uptake, giving indeterminate results. The aim of this study was to demonstrate the clinical usefulness of simultaneous co-registration of 99m Tc MDP bone scanning as an anatomical landmark with 1311 scanning in the evaluation of metastatic DTC.

Material and Methods:

Twenty-five patients (16 females and 9 males, mean age + SD = 52 + 13 years) with metastatic DTC (17 papillary, 8 follicular), were included. Whole body scanning were obtained 48 hours after oral administration of 185-370

MBq 1311 and 2 hours after IV administration of 185-370 MBq 99 mTc MDP. Occasionally, additional simultaneous co-registration of localized detailed images was also performed. The two planar images were fused with optional fusion of SPECT images. Fusion image were considered to improve image interpretation in comparison with standard 1311 scanning when they provided better localization of lesion.

الخلاصة

قلة التفاصيل التثويحية في معيل الودالمشع 131 للمسح لأرى الكامل للجسم تتداخل مع افضلية تحديد انتشار سوطان الغدة الوقية المتمايز بالاضافة في مكان قويب أو يتداخل مغوراً فى التريع الفيسو ولجى للود وذلك يعطى نتيجة غير محدده. هدف هذه الواسة كانت أن تَوْضَ الفائدة السوروية لتسجيل المشلك الآني مادة التكنثو م99 ةالمخل طه بالمادة الصيد لانية الميثالين داى فو سفو نيت فى المسح لأرى للعظام كمَعْلَم تثويحي مع الود 131 المشع فى مسحو تقيم انتشار سوطان الغدة الوقية المتمايز .

المادّةو الطوق

خمسة و عثيو ن و يض (16 أنثى و 9 ذكر ر، عُمر مق سط + الانحواف المعيل ى = 52 ±13 سَوَ ات) مَع انتشار سو طان الغدة الوقية (17 حُلَيمي، 8 و يصلي) اشتمل على المسح لأرى للعظام بعد 48ساعة من اعطاء جوعة الود بالفم بطاقة 185-370 ميقابيكريل و ساعتين من اعطاء جوعة وريدية من التكنشوم 99م المخل طه بالمادة الصيدلانية ميثالين داى فو سفو نيت بطاقة 185-370ميقابيكريل. بالاضافة الى ذلك تم دمج الصور تين المستخلصتين من القاما كموا المسطحه مع القاما كموا ثلاثية الابعاد. عملية دمج الصور ساهمت في تحسين وتفسير مع المقانة بااستعمال الود 131 و اعطنتا نتايج في تحديد و ضع العلة.

Table of Contents

| Acknowledgment | i |
|---------------------|-----|
| Dedication | ii |
| List of the figures | iii |
| Abstract | v |
| ألخلاصه | vi |
| Table of contents | vii |

List of Contents

| Chapter One Introduction | |
|-------------------------------|---|
| 1.1. Introduction | 1 |
| 1.2. Problem | 2 |
| 1.3. Objectives | 2 |
| Chapter Two Literature Review | |

| 2.1. Anatomy | 3 |
|---|------------|
| 2.2.Blood supply | 3 |
| 2.3. Nerves supply | 4 |
| 2.4. Histology | 4 |
| 2.5. Physiology | 5 |
| 2.5.1. Triiodothyronine | 6 |
| 2.5.2. Effects of thyroid hormones | 8 |
| 2.5.6. Pathology | 10 |
| 2.6.1. Features of benign thyroid nodule | 10 |
| 2.6.2. Features increase the suspicion of a malignant nodule1 | 0 |
| 2.6.3. Thyroid cancers | 11 |
| 2.6.4. Papillary carcinoma | 1 1 |
| 2.6.5. Follicular carcinoma | 11 |
| 2.7. Stages of the thyroid cancer | 11 |
| 2.7.1.1. Papillary and follicular | 11 |
| 2.7.2.1. Medullary | 12 |
| 2.7.2.1. Anaplastic | 12 |
| 2.8. Symptoms of thyroid cancer | 13 |
| 2.9. Complete history and physical examination | 13 |
| 2.10.Thyroid Scintigraphy1 | 4 |
| 2.11.Radionuclides for Thyroid Imaging and Measurements1 | 4 |
| 2.12. MDP (Methylene-diphosphonate) in-vivo kit for preparation | of |
| radiopharmaceutical product (Tc-IK-10) | 15 |
| 2.13. Field of indication | 15 |
| 2.13.1. Recommended mode of examination | 15 |

| 2.13.2. Contraindications | 15 |
|---|----|
| 2.13.2.1. Relative contraindications | 15 |
| 2.13.2.2. Absolute contraindications | 16 |
| 2.14. Radio-physical properties of the radionuclide and the absorbed dose value.16 | es |
| 2.15. Pharmaceutical particulars | 17 |
| 2.16. Incompatibilities | 17 |
| 2.16.1. Shelf life | 18 |
| 2.16.2. Special precautions for storage | 18 |
| 2.16.3. Instructions for use and handling | 18 |
| 2.16.4. Sodium Iodide I 131 | 19 |
| Chapter Three material & Methods | |
| 3.1. Material and Methods | 25 |
| 3.1.1.Scintigraphy procedures | 26 |
| 3.1.3.Fused 99mTc-MDP / 1311- WBS scanning | 26 |
| 3.1.4. Data processing and image fusion | 26 |
| Chapter Four Results | |
| 4.1. Results | 29 |

| 4.2. ¹³¹ 1 whole body scintigraphy (131I-WBS) | 29 |
|---|----|
| 4.3. ¹³¹ I-WBS and 99mTc-MDP bone scan fusion scintigraphy | 31 |
| Chapter Five Discussion | |
| 4.4. Discussion | 34 |
| 5.2. Conclusion | 39 |
| 5.3. Recommendations | 40 |
| References | 41 |

List of figure

| Figure 2.1 shows the anatomical lobes of the thyroid gland |
|---|
| Figure 2.3 shows the Arterial blood supply from the aortic arch for the thyroid |
| gland4 |
| Figure 2.4 shows the anatomical structure for thyroid |
| gland5 |

| Figure 2.5. Shows the chemical structure of thyroid hormones with iodine |
|--|
| attachment6 |
| Figure 2.6. Shows the chemical structure of thyroid hormones with iodine |
| attachment7 |
| Figure 2.6. Shows TSH release7 |
| Figure 2.6. Shows thyroid hormone response elements (TRE) in target |
| genes8 |
| Figure3.1: The difference in intensity scales and count per pixel for 99mTc-MDP |
| and 1322 scans. A. Figure shows the difference in count intensity between bone |
| for iodine and bone scale. Image manipulation entails the use of variable |
| multiplication factor (K) for 1-131 image followed by summation of iodine and |
| |
| bone scan images producing fused image with single intensity scale AB. |
| bone scan images producing fused image with single intensity scale AB.3-5 Images analysis and interpretation: |
| |
| 3-5 Images analysis and interpretation:27 |
| 3-5 Images analysis and interpretation: |

column) and fused scans (right column) in a female patient with multiple.

| Metastatic hot foci. The planar used image can not clarify totally the indicated |
|--|
| intra-thoracic lesion because of overlapping structures |
| Figure 4-2: Reconstructured transverse, sagittal and coronal slices for thoracic |
| region for the same patient showing the hot foci to be nodal mediational lesion. |
| |

List of table

| Table 2.1 showing the thyroid hormones levels in percentage |
|--|
| Table 2.2.shows the properties of the Tc-99m17 |
| Table 2.3 shows a single dose of a patient17 |
| Table 2.4 shows the list of Recipients17 |
| Table 2.4. Shows side effects or problems in older people |
| Table 3.1. shows the Patients' disease characteristics and frequency25 |
| Table 4.1. shows the sites of metastases from DTC |
| Table 4.2. shows the distribution of metastases by region |
| Table 4.4. Shows the findings of standard 1-131 and fused 1-131 /MDP bone |
| scan |
| Table 4.5. Shows the Effect fused planner I-131/MDP scans in identification of |
| indeterminate lesions |